At the Yacht Club de Monaco everything’s ready for the 2024 Optimist European Team Racing Championship final races ---
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
SiriusPoint reports eighth consecutive quarter of underwriting profits and seventh consecutive quarter of positive net income
NUAIR and SRAA Celebrate New Headquarters and Highlight Central New York’s Leadership in Advanced Air Mobility and Drone Innovation